GLMD Overview

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

Wall Street analysts forecast GLMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Galmed Pharmaceuticals Ltd revenue for the last quarter amounts to -2.10M USD, increased 4.18

Galmed Pharmaceuticals Ltd. EPS for the last quarter amounts to -1935000.00 USD, increased 81.86

Galmed Pharmaceuticals Ltd (GLMD) has 3 emplpoyees as of March 30 2026.

Today GLMD has the market capitalization of 3.32M USD.